drugset / Trial / NCT01381185

REsistance to Aspirin and Clopidogrel in acuTe Myocardial Infarction

NCT01381185 ↗

Phase 4 Completed 154 enrolled University Hospital Ostrava
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to compare 3 point-of-care methods for monitoring antiplatelet therapy to golden standard (Light transmittance aggregometry-LTA) in high risk population of acute myocardial infarction patients. If two methods (PFA-100, VerifyNOW,Multiplate or LTA) will indicate insufficient antiplatelet blockade/high residual reactivity for aspirin, clopidogrel or both, the dose of aspirin will be increased to 200mg qd and the dose of clopidogrel will be increased to 2x75mg qd.In addition genotyping of CYP2C19 (6 alleles) will be performed.

Timeline

Start
2011-05
Primary completion
2015-06
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 200 mg —
Comparator Clopidogrel Small molecule 75 mg —